glp-1 receptor agonists in pediatric and adolescent obesity prescribing among teens with Current Insights, Advantages and Challenges

A novel glucagon-like peptide-1/glucagon receptor dual agonist exhibits weight-lowering and diabetes-protective effects

Haadia Waheed, orcid.org/0009-0005-4387-1580

& Najarian, R

For consumer goods companies, this represents both a challenge and an opportunity

Still, insurance coverage and cost considerations mean both drugs remain relevant, and patient-centred conversations about therapy choice are critical. GLP-1s beyond weight loss as multi-system therapies Liver disease and metabolic steatohepatitis Non-alcoholic fatty liver disease (NAFLD) and the more severe metabolic dysfunction-associated steatohepatitis (MASH) have few effective pharmacologic treatments